---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-22-000040"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2022-07-28T23:59:59+00:00"
generated_at: "2026-06-24T07:19:12.125066+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q2 revenue $691M down 3.5% YoY; non-GAAP EPS $3.38; raises FY22 revenue outlook; adds $200M buyback

## Summary
- Q2 GAAP net loss $927M ($31.12/diluted) vs income $914M ($30.32) last year; non-GAAP net income $101M ($3.38) vs $107M ($3.54).
- Reported sales $691.1M down 3.5% YoY; currency-neutral core sales (ex-COVID) up 5.7%.
- Life Science $322M (-3.5% reported, +0.5% constant); Clinical Diag $368M (-3.3%, +0.7% constant).
- FY22 guidance: non-GAAP currency-neutral revenue growth at high end of 1-2%; COVID rev ~$93M (up); op margin ~19% reaffirmed.
- Board authorized additional $200M share repurchase; total available $298.1M.

## SEC filing metadata
- accession: 0000012208-22-000040
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2022-07-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220822000040/0000012208-22-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220822000040/bio-20220728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-22-000040
- JSON: https://secwatch.observer/filing/0000012208-22-000040.json
- Plain text: https://secwatch.observer/filing/0000012208-22-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.